TITLE

Intravenous immunoglobulin improved clinical outcomes in patients with myasthenia gravis and worsening weakness: COMMENTARY

AUTHOR(S)
Nicolle, Michael W.
PUB. DATE
September 2007
SOURCE
ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p50
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article offers the author's comments on intravenous immunoglobulin (IVIG) improved clinical outcomes in patients with myasthenia gravis (MG) and worsening weakness. It is stated that acute severe bulbar or respiratory weakness, a myasthenic crisis, can be life-threatening. It suggests that IVIG and plasma exchange (PLEX) are equally effective in cases of significant weakness.
ACCESSION #
27029986

 

Related Articles

  • Intravenous immunoglobulin improved clinical outcomes in patients with myasthenia gravis and worsening weakness.  // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p50 

    The article discusses the effectiveness of intravenous immunoglobulin in improving the clinical outcomes in patients with myasthenia gravis and worsening weakness. It is stated that in patients with myasthenia gravis and worsening weakness, intravenous immunoglobulin (2 g/kg) was more effective...

  • Autonomic 'myasthenia': the case for an autoimmune pathogenesis. Drachman, Daniel B. // Journal of Clinical Investigation;3/15/2003, Vol. 111 Issue 6, p797 

    Presents the criteria for recognizing antibody-mediated autoimmune disease. Presence of autoantibodies in patients with the disease; Interaction of the antibody with the target antigen; Reduction of antibody levels.

  • Successful low-dose azathioprine for myasthenia gravis despite hepatopathy from primary sclerosing cholangitis: a case report. Finsterer, Josef; Höflich, Sonja // Journal of Medical Case Reports;2010, Vol. 4 Issue 1, p1 

    Introduction: Although myasthenia gravis is frequently associated with other disorders, it has not been reported together with primary sclerosing cholangitis, complicating the administration of liver-toxic immunosuppressive therapy. Case presentation: A 73-year-old Caucasian woman with a history...

  • Postoperative myasthenic crisis successfully treated with immunoadsorption therapy. Ishizeki, Junko; Nishikawa, Koichi; Kunimoto, Fumio; Goto, Fumio // Journal of Anesthesia;2005, Vol. 19 Issue 4, p320 

    Myasthenia gravis (MG) is an autoimmune disorder characterized by loss of acetylcholine receptors (AChR) due primarily to the production of anti-AChR autoantibodies. We report a case of MG associated with elevated anti-acetylcholine receptor antibody (anti-AChR Ab) and refractory crisis after...

  • Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. Dalakas, Marinos C. // JAMA: Journal of the American Medical Association;5/19/2004, Vol. 291 Issue 19, p2367 

    Context Intravenous immunoglobulin (IVIG) enhances immune homeostasis by modulating expression and function of Fc receptors, interfering with activation of complement and production of cytokines, providing anti-idiotypic antibodies, and affecting the activation and effector functions of T and B...

  • Myasthenic Antibodies and Disease Phenotype. Rubin, Michael // Neurology Alert;Feb2013, Vol. 31 Issue 6, p43 

    The article discusses the author's views on a study regarding the clinical differences in patients with myasthenia gravis (MG) based on the type of existing antibody. The author explains that patients with MG demonstrate antibodies in the serum directed against acetylcholine receptor antibodies,...

  • Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands. Niks, Erik H.; Kuks, Jan B. M.; Verschuuren, Jan J. G. M. // Journal of Neurology, Neurosurgery & Psychiatry;Apr2007, Vol. 78 Issue 4, p417 

    The epidemiology of myasthenia gravis subtypes and the frequency of antibodies to muscle-specific kinase (MuSK) was studied in patients with generalised myasthenia gravis without anti-acetylcholine receptor antibodies who had an onset of symptoms between 1990 and 2004 in a well-defined region in...

  • Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. Nemoto, Y.; Kuwabara, S.; Misawa, S.; Kawaguchi, N.; Hattori, T.; Takamori, M.; Vincent, A. // Journal of Neurology, Neurosurgery & Psychiatry;May2005, Vol. 76 Issue 5, p714 

    Objectives: To compare the clinical and electrophysiological features of myasthenia gravis (MG) patients with (seropositive) or without (seronegative) antibodies to acelylcholine receptor. To investigate whether antibodies to muscle specific kinase (MuSK) and ryanodine receptor (RyR) are...

  • Muscle autoantibodies in subgroups of myasthenia gravis patients. Romi, Fredrik; Skeie, Geir Olve; Aarli, Johan A.; Gilhus, Nils Erik // Journal of Neurology;May2000, Vol. 247 Issue 5, p369 

    Myasthenia gravis (MG) is caused by autoantibodies to the acetylcholine receptor (AChR), but several other muscle autoantibodies have also been identified in patient sera. We studied muscle autoantibodies against AChR, striated muscle tissue sections (SH), titin, citric acid antigen (CA), and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics